The Effectiveness of Drug Treatment for Depressive Symptoms

Author:

Xu Xinya

Abstract

Because most of the current therapies for the treatment of mental disorders such as depression are cognitive behavioral therapy, the treatment time is too long for people with major depression who face serious threats of suicide, and the symptoms cannot be alleviated in time when the onset of this kind of treatment is not suitable for them. Medication is another option for treatment, although in the case of depression that resists therapy, a type of severe depression, few antidepressants are effective to them. If left untreated, this type of depression might result in suicide since those who experience it have little desire to live and are gloomy. Therefore, people with treatment-resistant depression have a higher suicide rate. In this paper, esketamine (a kind of ketamine), one of the few fast antidepressant drugs that can play a role, will be mentioned, and the therapeutic effect and safety of such drugs will be analyzed, and the efficacy of different people will be compared in depth. In addition, there is a wonder drug in the development process - ayahuasca will be mentioned and compared with ketamine drugs. It becomes clear that the research presented in this essay still has some weaknesses. The areas that need to be improved will next be demonstrated using examples. The usage and inadequacy of ayahuasca will also be assessed in this essay at the same time.

Publisher

Darcy & Roy Press Co. Ltd.

Reference10 articles.

1. Gartlehner G., Wagner G., Matyas N., Titscher V., Greimel J., Lux L., Gaynes B. N., Viswanathan M., Patel S., Lohr K. N. Pharmacological and non-pharmacological treatments for major depressive disorder: Review of systematic reviews. BMJ Open, 2017, 7(6): e014912.

2. Czéh B., Simon M. Benefits of animal models to understand the pathophysiology of depressive disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 106: 110049.

3. Fedgchin M., Trivedi M., Daly E. J., Melkote R., Lane R., Lim P., Vitagliano D., Blier P., Fava M., Liebowitz M., Ravindran A., Gaillard R., Ameele H. V. D., Preskorn S., Manji H., Hough D., Drevets W. C., Singh J. B. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: Results of a randomized, double-blind, active-controlled study (TRANSFORM-1). The International Journal of Neuropsychopharmacology, 2019, 22(10): 616–630.

4. Katz E. G., Hough D., Doherty T., Lane R., Singh J., Levitan B. Benefit–risk assessment of esketamine nasal spray vs. Placebo in treatment‐resistant depression. Clinical Pharmacology & Therapeutics, 2021, 109(2): 536–546.

5. Doty R. L., Popova V., Wylie C., Fedgchin M., Daly E., Janik A., Ochs-Ross R., Lane R., Lim P., Cooper K., Melkote R., Jamieson C., Singh J., Drevets W. C. Effect of esketamine nasal spray on olfactory function and nasal tolerability in patients with treatment-resistant depression: Results from four multicenter, randomized, double-blind, placebo-controlled, phase iii studies. CNS Drugs, 2021, 35(7): 781–794.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3